Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UG1HD034216 | U.S. NIH Grant/Contract | View source | |
| UG1HD027904 | U.S. NIH Grant/Contract | View source | |
| UG1HD021364 | U.S. NIH Grant/Contract | View source | |
| UG1HD027853 | U.S. NIH Grant/Contract | View source | |
| UG1HD040689 | U.S. NIH Grant/Contract | View source | |
| UG1HD040492 | U.S. NIH Grant/Contract | View source | |
| UG1HD027851 | U.S. NIH Grant/Contract | View source | |
| UG1HD087229 | U.S. NIH Grant/Contract | View source | |
| UG1HD053109 | U.S. NIH Grant/Contract | View source | |
| UG1HD068278 | U.S. NIH Grant/Contract | View source | |
| UG1HD068244 | U.S. NIH Grant/Contract | View source | |
| UG1HD068263 | U.S. NIH Grant/Contract | View source | |
| UG1HD027880 | U.S. NIH Grant/Contract | View source | |
| UG1HD053089 | U.S. NIH Grant/Contract | View source | |
| UG1HD087226 | U.S. NIH Grant/Contract | View source | |
| UG1HD112079 | U.S. NIH Grant/Contract | View source | |
| UG1HD112097 | U.S. NIH Grant/Contract | View source | |
| UG1HD112100 | U.S. NIH Grant/Contract | View source | |
| 3U24HD095254-07 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA).
Were they not delivered early, extremely premature infants would normally develop in darkness within the uterus for 3-4 more months longer before birth. Yet, the routine care of these infants has involved the use of uninterrupted (continuous) exposure to bright light during phototherapy (PT), a treatment method that neonatologists have assumed has no serious adverse effects on even the most immature of newborns.
Immaturity, thin translucent skin, and a multitude of other problems may make extremely premature infants highly vulnerable to the photo-oxidative injury, lipid peroxidation, DNA damage, reduced cerebral and mesenteric blood flow, or other serious potential hazards of uninterrupted exposure to PT that have now been identified. Such hazards were not recognized when continuous PT was widely incorporated into neonatal care, and the survival rate of extremely premature infants (<27 wks gestation or <750 g birth weight) was much lower than today.
PT rapidly photoisomerizes bilirubin in the subcutaneous tissues and vasculature, and six trials of cycled PT have demonstrated that use of cycled PT reduces the total hours of PT and results in minimal or no increase in peak TSB over that with continuous PT in term or moderately preterm infants. Recent findings from a pilot study (NCT01944696) support a PT regimen for this Cycled Phototherapy protocol.
Infants born at one of the Neonatal Research Network centers, ≤ 750 grams at birth and/or < 27 weeks gestation at birth by best OB estimate will be considered for this study.
Those who qualify will be randomized to either cycled PT or continuous PT. The cycled phototherapy begins with >15 min/h cycled PT regimen and increased to 30 min/h if the TSB is 8.0-9.9 and 60 min/h if the TSB is >10 mg/dL. Those randomized to continuous phototherapy will undergo continuous exposure,as that is commonly used in NRN centers.
The PT lamp position will be adjusted to meet the irradiance (µW/cm2/nm) goal of 22 at the umbilicus. The irradiance goal in both groups will be increased from 22 to 33 at a TSB of 10-13 and to 40 at a TSB >13.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous Phototherapy | Active Comparator | Continuous phototherapy |
|
| Cycled Phototherapy | Experimental | Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Phototherapy lights | Device | Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants survival to discharge | Number of Participants discharged from hospital alive, after birth. | Birth to hospital discharge, up to 120 days of life |
| Measure | Description | Time Frame |
|---|---|---|
| Number of hours of Phototherapy | The reported values will be the mean total hours of phototherapy during the two week intervention period. | Start until the end of intervention period (duration of 2 weeks) |
| Number of irradiance hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jon Tyson, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | United States | ||
| Stanford University |
NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov)
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 30, 2022 | Jun 15, 2026 |
Not provided
Pragmatic randomized clinical trial addressing patient safety.
Not provided
Not provided
Not provided
The reported values will be the mean total hours of irradiance during the two week intervention period.
| Start until the end of intervention period (duration of 2 weeks) |
| Peak Concentration of Total Serum Bilirubin | The reported values will be the mean peak total serum bilirubin (mg/dL) during the two week intervention period. | Start until the end of intervention period (duration of 2 weeks) |
| Concentration of Total Serum Bilirubin | The reported values will be the mean total serum bilirubin (mg/dL) during the two week intervention period. | Start until the end of intervention period (duration of 2 weeks) |
| Number of Participants with Major neonatal morbidity | Major neonatal morbidity is defined as a severe ICH, ventricular enlargement of cystic white matter disease, BPD, late onset sepsis, NEC or spontaneous intestinal perforation, or >grade 3 ROP before discharge. | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Severe ICH, as a component of the predischarge morbidity | As recorded for the sonongram with the most severe finding in the blood/echodensity in the ventricle or blood/echodensity in the parenchyma | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Ventricular enlargement of cystic white matter disease, as a component predischarge morbidity | If a MRI was done: ventricular size enlarged, cystic PVL or porencephalic /posthemorrhagic cyst/multicystic encephalomalacia observed. If a MRI was not done: the same items as above for sonograms after day 28. | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Bronchopulmonary dysplasia (BPD), as a component predischarge morbidity | BPD defined as highest FiO2 at 36 wk: >0.21 | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Late onset sepsis, as a component predischarge morbidity | Late onset blood culture positive septicemia/bacteremia at >72 hours of age. | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Necrotising enterocolitis (NEC) or spontaneous intestinal perforation, as a component predischarge morbidity | Either proven NEC or spontaneous gastrointestinal perforation without proven NEC. | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Grade 3 (or greater) retinopathy of prematurity (ROP), as a component predischarge morbidity | Stage 3 ROP observed in either eye. | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Patent ductus arteriosus (PDA) treated with surgery or NSAIDS | PDA treated with surgery or NSAIDS (indomethacin, ibuprofen or acetaminophen) | Birth to hospital discharge, up to 120 days of life |
| Number of Participants with Neurodevelopmental Impairment | Neurodevelopmental Impairment (NDI), as assessed in a sub-population of follow-up of infants <27 wks gestation. Severe NDI will be defined by any of the following: a BSID III cognitive score < 70, Gross Motor Functional (GMF) Level of 3-5, blindness (<20/200 vision) or profound hearing loss (inability to understand commands despite amplification); moderate NDI will be defined as a BSID III cognitive score 70-84 and either a GMF level of 2 or a hearing deficit requiring amplification to understand commands or unilateral blindness; mild NDI will be defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMF level 1 or hearing loss not requiring amplification. Normal (no NDI) will be defined by a cognitive score ≥ 85 and absence of any neurosensory deficits. | Birth to 26 months corrected age |
| Number of Participants with Neurodevelopmental Impairment or Death | NDI defined in outcome #9 | Birth to 26 months corrected age |
| Palo Alto |
| California |
| 94304 |
| United States |
| Sharp Mary Birch Hospital for Women & Newborns | San Diego | California | 92123 | United States |
| Emory University | Atlanta | Georgia | 30303 | United States |
| Northwestern Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | United States |
| University of Iowa | Iowa City | Iowa | 52242 | United States |
| University of Mississippi Medical Center - Children's of Mississippi | Jackson | Mississippi | 39216 | United States |
| University of New Mexico | Albuquerque | New Mexico | 87131 | United States |
| University of Rochester | Rochester | New York | 14642 | United States |
| RTI International | Durham | North Carolina | 27705 | United States |
| Duke University | Durham | North Carolina | 27710 | United States |
| Cincinnati Children's Medical Center | Cincinnati | Ohio | 45267 | United States |
| Case Western Reserve University, Rainbow Babies and Children's Hospital | Cleveland | Ohio | 44106 | United States |
| Research Institute at Nationwide Children's Hospital | Columbus | Ohio | 43205 | United States |
| Univeristy of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Brown University - Women and Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | United States |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75235 | United States |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
| University of Utah | Salt Lake City | Utah | 84108 | United States |
| Prot_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Mar 30, 2022 | Jun 15, 2026 | ICF_001.pdf |
| ID | Term |
|---|---|
| D047928 | Premature Birth |
| D007232 | Infant, Newborn, Diseases |
| ID | Term |
|---|---|
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided